EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Head-to-head comparison of neurodegeneration biomarkers across two analytical platforms in Alzheimer’s disease

Carolin Kurz, Daniela Hattenkofer, Maximilian Pihale-Haug, Anna Hufnagel, Selim Üstün Gürsel, Matthias Brendel, Boris-Stephan Rauchmann, Johannes Levin, Günter Höglinger, Robert Perneczky

Aging Clinical and Experimental Research · 25.06.2026 · 38 (1)

DOI: 10.1007/s40520-026-03420-5 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Aging Clinical and Experimental Research, online erschienen am 25.06.2026. Verfasst von Carolin Kurz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychotherapy, LMU Hospital LMU Munich, 80336, Munich, Germany. carolin.kurz@mri.tum.de. Hauptthemen laut MEDLINE: Alzheimer Disease, Biomarkers. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Klinikum der Universität München.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Blood-based biomarkers are increasingly used to support the identification of Alzheimer’s disease (AD) in clinical and research settings. However, variability between analytical platforms limits their interchangeability and may affect their clinical interpretation. Direct head-to-head comparisons across assays and their alignment with clinical phenotypes remain limited.

Objective

To compare the inter-test agreement of blood-based biomarkers measured using Roche and Fujirebio assays and to determine which biomarker shows the most robust analytical concordance and clinical relevance in AD.

Methods

Participants with AD (n = 86) and cognitively healthy controls (HC; n = 56) underwent blood biomarker assessment using Roche and Fujirebio platforms. Plasma phosphorylated tau at threonine 217 (pTau217), plasma phosphorylated tau at threonine 181 (pTau181), Amyloid-β42 (Aβ42), amyloid-β40 (Aβ40), and the amyloid-β42/amyloid-β40 ratio (Aβ42/Aβ40) and glial fibrillary acidic protein (GFAP) were analyzed. Inter-test agreement was assessed using intraclass correlation coefficients, concordance analyses, and regression-based methods. Clinical relevance was evaluated by association with measures of cognitive and functional impairment evaluated using the Mini-Mental State Examination (MMSE) and the Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB). Analyses were adjusted for age and sex and complemented by sensitivity and stability analyses.

Results

Inter-test agreement varied across biomarkers, with pTau217 demonstrating the highest and most stable concordance between Roche and Fujirebio assays. Among the evaluated markers, pTau217 also showed the strongest and most consistent associations with global cognition measures across diagnostic groups and best discriminated between individuals with AD and HC. GFAP demonstrated robust inter-test agreement but weaker alignment with clinical measures, while amyloid-based markers showed lower concordance and greater variability across platforms.

Conclusions

Head-to-head comparison of Roche and Fujirebio assays revealed biomarker-specific differences in inter-test agreement, limiting the direct interchangeability of measurements across platforms. Plasma pTau217 showed the most consistent analytical concordance and clinical associations in this setting, supporting its potential utility in cross-platform applications. However, these findings also highlight the need for assay-specific calibration and cautious interpretation of biomarker thresholds in clinical and research use and the need for further validation across diverse populations.

Trial registration

NCT05059158, NCT05317871

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseBiomarkersAgedAged, 80 and overFemaleHumansMaleAmyloid beta-PeptidesGlial Fibrillary Acidic ProteinPeptide Fragmentstau ProteinsObservational Studies as Topic

Stichwörter der Autor:innen

Alzheimer disease/bloodBiomarkers/bloodBlood-based biomarkersGlial fibrillary acidic protein/bloodInter-test agreementNeurodegenerationpTau217/blood

Substanzen

Amyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersGlial Fibrillary Acidic ProteinPeptide Fragmentstau Proteins

Autor:innen und Institutionen

  • Department of Psychiatry and Psychotherapy, LMU Hospital LMU Munich, 80336, Munich, Germany. carolin.kurz@mri.tum.de.
  • Department of Psychiatry and Psychotherapy, LMU Hospital LMU Munich, 80336, Munich, Germany.
  • German Center for Neurodegenerative Diseases (DZNE), 81377, Munich, Germany.
  • Department of Nuclear Medicine, LMU Hospital LMU Munich, 81377, Munich, Germany.
  • Munich Cluster for Systems Neurology (SyNergy), 80336, Munich, Germany.
  • Department of Radiology, LMU Hospital LMU Munich, 81377, Munich, Germany.

Förderung

  • Klinikum der Universität München

Zitieren

APA

Kurz, C., Hattenkofer, D., Pihale-Haug, M., Hufnagel, A., Gürsel, S. Ü., Brendel, M., Rauchmann, B. S., Levin, J., Höglinger, G., & Perneczky, R. (2026). Head-to-head comparison of neurodegeneration biomarkers across two analytical platforms in Alzheimer’s disease. Aging Clinical and Experimental Research, 38(1). https://doi.org/10.1007/s40520-026-03420-5

Vancouver

Kurz C, Hattenkofer D, Pihale-Haug M, Hufnagel A, Gürsel SÜ, Brendel M, et al. Head-to-head comparison of neurodegeneration biomarkers across two analytical platforms in Alzheimer’s disease. Aging Clinical and Experimental Research. 2026;38(1). doi:10.1007/s40520-026-03420-5

BibTeX
@article{Kurz2026,
  author = {Kurz, Carolin and Hattenkofer, Daniela and Pihale-Haug, Maximilian and Hufnagel, Anna and Gürsel, Selim Üstün and Brendel, Matthias and Rauchmann, Boris-Stephan and Levin, Johannes and Höglinger, Günter and Perneczky, Robert},
  title = {Head-to-head comparison of neurodegeneration biomarkers across two analytical platforms in Alzheimer’s disease},
  journal = {Aging Clinical and Experimental Research},
  year = {2026},
  volume = {38},
  number = {1},
  doi = {10.1007/s40520-026-03420-5}
}
Kostenlos starten →